Technical University Of Munich
Clinical trials sponsored by Technical University Of Munich, explained in plain language.
-
Could a common drug slow down this rare brain disease?
Disease control OngoingThis phase 2 trial tests whether glycerol phenylbutyrate (GPB) can slow corticobasal syndrome (CBS), a rare and fast-progressing brain disease. 32 adults with CBS will receive either GPB or a placebo for 26 weeks. The main goal is to see if GPB lowers levels of a nerve damage mar…
Phase: PHASE2 • Sponsor: Technical University of Munich • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Could an existing eczema drug help a rare skin condition?
Disease control OngoingThis Phase 2 trial tests dupilumab (Dupixent), an injectable drug already approved for atopic dermatitis, in 70 adults with nummular eczema, a chronic, itchy skin condition. Participants receive either dupilumab or a placebo for several weeks. The study measures changes in eczema…
Phase: PHASE2 • Sponsor: Technical University of Munich • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Could a 30-Year-Old blood vessel drug ease Parkinson's?
Symptom relief OngoingThis phase 2 trial tests whether fasudil, a drug already used in Japan for blood vessel spasms, is safe and can help symptoms in people with early Parkinson's disease. 75 participants will take either fasudil or a placebo for 3 weeks. The study focuses on safety and tolerability,…
Phase: PHASE2 • Sponsor: Technical University of Munich • Aim: Symptom relief
Last updated Jul 02, 2026 00:00 UTC